Posted: 07/10/2025 03:53 am
Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company, remains active in the development of immune-oncology therapeutics through its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies. While the company embarks on innovation and trials, attention also revolves around the compensation awarded to its executives, notably Marvin L. White, the Chief Executive Officer and President of Aptevo.
In 2024, Marvin L. White's total compensation was $906,020, reflecting a slight decrease from his 2022 compensation of $1,171,168. Notably, his compensation package remains devoid of bonuses, stock awards, or option awards for these years. The primary components of his earnings include an annual salary of $575,000 in 2024 and $565,123 in 2022, with substantial additions from incentive plan compensation—$316,250 in 2024 and $318,588 in 2022—and minor contributions from all other compensations, accounting for $10,350 in 2024 and $9,150 in 2022.[1][2][3] This compensation arrangement highlights a strategic focus on short-term incentives tied to performance, while the lack of equity-based incentives indicates a conservative stance on longer-term compensatory risk-sharing that is often utilized in high-growth industries to align executives with shareholders' interests.
Compensation aside, Aptevo is making notable strides in clinical achievements and innovation. The announcement of completing multiple phases of its RAINIER trial, where nearly all patients achieved rapid remission with a favorable safety profile, underscores significant advancements in its therapeutic offerings, particularly for acute myeloid leukemia (AML).[4] This narrative of progress was further emphasized in recent discussions at industry conferences and public communications, where Aptevo's innovations and ongoing trials took center stage, promising a strong pipeline for future developments in cancer treatment.[5][6]
Financial outcomes and progress updates continue to bolster investor interest despite recent fluctuations in stock price, currently priced at $3.04 per share, as of the latest trading session.[7] With the market reacting to ongoing clinical results and financial disclosures, Aptevo's focused progression in oncology treatment through innovative platforms indicates both opportunity and risk management as it navigates the complex landscape of biotechnology advancements.
1. SEC Filing: Aptevo Therapeutics Inc. Compensation Data for 2024 [link](https://www.sec.gov/Archives/edgar/data/1671584/000095017025093924/0000950170-25-093924-index.htm).
2. SEC Filing: Aptevo Therapeutics Inc. Compensation Data for 2022 [link](https://www.sec.gov/Archives/edgar/data/1671584/000095017024046881/0000950170-24-046881-index.htm).
3. SEC Filing: Aptevo Therapeutics Inc. Compensation Data for 2022 [link](https://www.sec.gov/Archives/edgar/data/1671584/000095017023072644/0000950170-23-072644-index.htm).
4. Access Newswire: Aptevo Therapeutics Reports 2024 Financial Results and Provides a Business Update [link](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aptevo-therapeutics-reports-2024-financial-results-and-provides-an-up-1028089).
5. Access Newswire: Aptevo's Programs and Innovations [link](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aptevo-therapeutics-provides-program-update-for-bispecific-apvo711-a-1025386).
6. Accesswire: Aptevo's Conference Presentation on Therapeutic Design [link](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aptevo-highlights-apvo603-a-novel-bispecific-antibody-targeting-4-1bb--998824).
7. NASDAQ Stock Exchange Current Price Snapshot: Aptevo Therapeutics Inc. [link](https://www.nasdaq.com/market-activity/stocks/apvo).
